AROLDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 1.207
EU - Europa 657
AS - Asia 171
SA - Sud America 3
Totale 2.038
Nazione #
US - Stati Uniti d'America 1.201
IT - Italia 263
IE - Irlanda 131
DE - Germania 127
SE - Svezia 81
CN - Cina 63
HK - Hong Kong 48
GB - Regno Unito 18
SG - Singapore 18
IN - India 14
FI - Finlandia 13
VN - Vietnam 12
TR - Turchia 11
CA - Canada 6
FR - Francia 5
PL - Polonia 5
UA - Ucraina 4
BG - Bulgaria 3
IR - Iran 2
NO - Norvegia 2
RS - Serbia 2
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
CO - Colombia 1
DK - Danimarca 1
ID - Indonesia 1
JP - Giappone 1
KR - Corea 1
NL - Olanda 1
Totale 2.038
Città #
Ann Arbor 545
Dublin 131
Frankfurt am Main 113
Chandler 86
Milan 78
New York 73
Fairfield 70
Wilmington 68
Woodbridge 62
Hong Kong 42
Ashburn 36
Seattle 34
Houston 31
Princeton 24
Cambridge 20
Shanghai 20
Lissone 19
Lawrence 12
Altamura 11
Monza 10
Helsinki 9
Rome 9
Bologna 8
Dong Ket 8
Jacksonville 8
San Diego 8
Beijing 7
Dearborn 7
Guangzhou 7
Boardman 6
Carate Brianza 6
Fremont 6
London 6
Los Angeles 6
Andover 5
Tianjin 5
Bonndorf 4
Falls Church 4
Lodz 4
Pune 4
Sacramento 4
Sesto San Giovanni 4
Turin 4
Ankara 3
Arese 3
Colorado Springs 3
Corbetta 3
Delhi 3
Kocaeli 3
Lappeenranta 3
Legnano 3
Nanchang 3
Seriate 3
Toronto 3
Usmate Velate 3
Agrate Brianza 2
Aurora 2
Cesano Maderno 2
Cinisello Balsamo 2
Como 2
Desio 2
Genoa 2
Haikou 2
Hounslow 2
Jiaxing 2
Jinan 2
Kragujevac 2
Latina 2
Marino 2
Marseille 2
Milton Keynes 2
Mumbai 2
Nanjing 2
Nova Milanese 2
Oslo 2
Pavia 2
Redmond 2
Rho 2
Shantou 2
Sumirago 2
Treviglio 2
Veniano 2
Vimodrone 2
Véretz 2
Washington 2
Altivole 1
Americana 1
Anguillara Sabazia 1
Arcene 1
Arzano 1
Baotou 1
Bogotá 1
Borgarello 1
Breganzona 1
Brindisi 1
Bytom 1
Cantu 1
Carpi 1
Casorate Primo 1
Casoria 1
Totale 1.735
Nome #
Chronic myeloid leukemia: Second-line drugs of choice 256
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 173
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 167
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 162
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 155
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 142
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 140
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 139
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 125
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 98
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 91
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 65
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 64
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 61
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 53
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 43
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 40
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 39
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 34
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 28
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 24
Idiopathic erythrocytosis: a germline disease? 20
Totale 2.119
Categoria #
all - tutte 7.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.101


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201914 0 0 0 0 0 0 0 0 0 0 6 8
2019/2020103 6 1 4 10 9 12 10 17 11 13 5 5
2020/2021663 37 17 66 57 58 75 58 60 69 47 58 61
2021/2022295 52 36 48 38 14 23 4 8 7 10 17 38
2022/2023421 37 117 37 27 24 62 29 8 35 12 26 7
2023/2024560 14 20 30 27 61 175 96 25 67 42 3 0
Totale 2.119